SCHEMBL3650490

SCHEMBL3650490

OCc1ccc(N2CCOCC2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
JAK2 O60674 1/20 0.47
AKR1C3 P42330 1/20 0.47
MAPT P10636 5/20 0.46
HRH3 Q9Y5N1 2/20 0.44
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 3/20 0.44
MEN1 O00255 3/20 0.44
HTT P42858 3/20 0.44
KMT2A Q03164 3/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
GSK3B P49841 1/20 0.44
ALOX15 P16050 2/20 0.44
RAB9A P51151 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18115210 0.87 POLB (0.49) POLBAKR1C3MAPTALDH1A1KDM4E
SCHEMBL807518 0.83 POLB (0.51) POLBAKR1C3MAPTALDH1A1KDM4E
SCHEMBL8194202 0.83 POLB (0.51) POLBAKR1C3MAPTALDH1A1KDM4E
SCHEMBL18929856 0.81 POLB (0.49) POLBAKR1C3MAPTALDH1A1KDM4E
SCHEMBL30922297 0.80 CHKA (0.51) MAPTHRH3ALDH1A1KDM4EMEN1
SCHEMBL4024508 0.80 CHRNB2 (0.58) HRH3KDM4E
SCHEMBL16260486 0.80 POLB (0.48) POLBAKR1C3MAPTALDH1A1KDM4E
SCHEMBL31073166 0.79 HRH3 (0.44) HRH3
SCHEMBL20582236 0.78 POLB (0.47) POLBJAK2AKR1C3MAPTALDH1A1
SCHEMBL3853696 0.76 HRH3 (0.53) AKR1C3HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311748-A1 HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS ASTRAZENECA AB (SE) 2010-12-09 US disclosed
CN-101835752-A Heterocyclic amides useful for the treatment of cancer and psoriasis ASTRAZENECA AB 2010-09-15 CN disclosed
EP-2188255-A1 HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS AstraZeneca AB (SE) 2010-05-26 EP disclosed
WO-2009027746-A1 HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS ASTRAZENECA AB (SE) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311748-A1 HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS SHH, GLI1, HRH4 POLB 3524/4885JAK2 135/4885AKR1C3 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.